ASX - By Stock
|
NEU |
Re:
Ann: Investor Presentation, 14 March 2023
|
|
sillazze
|
145 |
72K |
46 |
16/03/23 |
16/03/23 |
ASX - By Stock
|
145
|
72K
|
46
|
|
ASX - By Stock
|
NEU |
Re:
Acadia
|
|
sillazze
|
677 |
329K |
30 |
12/03/23 |
12/03/23 |
ASX - By Stock
|
677
|
329K
|
30
|
|
ASX - By Stock
|
NEU |
Re:
Acadia
|
|
sillazze
|
677 |
329K |
25 |
11/03/23 |
11/03/23 |
ASX - By Stock
|
677
|
329K
|
25
|
|
ASX - By Stock
|
NEU |
Re:
Acadia
|
|
sillazze
|
677 |
329K |
26 |
11/03/23 |
11/03/23 |
ASX - By Stock
|
677
|
329K
|
26
|
|
ASX - By Stock
|
NEU |
Re:
FDA Approval
|
|
sillazze
|
116 |
52K |
37 |
11/03/23 |
11/03/23 |
ASX - By Stock
|
116
|
52K
|
37
|
|
ASX - By Stock
|
NEU |
Re:
Good Luck and Thanks to All
|
|
sillazze
|
21 |
11K |
67 |
10/03/23 |
10/03/23 |
ASX - By Stock
|
21
|
11K
|
67
|
|
ASX - By Stock
|
NEU |
Re:
Share Price
|
|
sillazze
|
11K |
5.4M |
18 |
09/03/23 |
09/03/23 |
ASX - By Stock
|
11K
|
5.4M
|
18
|
|
ASX - By Stock
|
NEU |
Re:
FDA
|
|
sillazze
|
122 |
48K |
14 |
08/03/23 |
08/03/23 |
ASX - By Stock
|
122
|
48K
|
14
|
|
ASX - By Stock
|
NEU |
Re:
FDA
|
|
sillazze
|
122 |
48K |
21 |
08/03/23 |
08/03/23 |
ASX - By Stock
|
122
|
48K
|
21
|
|
ASX - By Stock
|
NEU |
Re:
FDA
|
|
sillazze
|
122 |
48K |
21 |
08/03/23 |
08/03/23 |
ASX - By Stock
|
122
|
48K
|
21
|
|
ASX - By Stock
|
NEU |
Re:
FDA
|
|
sillazze
|
122 |
48K |
26 |
08/03/23 |
08/03/23 |
ASX - By Stock
|
122
|
48K
|
26
|
|
ASX - By Stock
|
NEU |
Re:
Ann: Rett Syndrome NDA accepted for Priority Review by FDA
|
|
sillazze
|
163 |
82K |
12 |
27/02/23 |
27/02/23 |
ASX - By Stock
|
163
|
82K
|
12
|
|
ASX - By Stock
|
NEU |
Re:
Ann: Rett Syndrome NDA accepted for Priority Review by FDA
|
|
sillazze
|
163 |
82K |
26 |
26/02/23 |
26/02/23 |
ASX - By Stock
|
163
|
82K
|
26
|
|
ASX - By Stock
|
NEU |
Re:
Ann: Application for quotation of securities - NEU
|
|
sillazze
|
3 |
2.8K |
24 |
21/02/23 |
21/02/23 |
ASX - By Stock
|
3
|
2.8K
|
24
|
|
ASX - By Stock
|
NEU |
Re:
Ann: Rett Syndrome NDA accepted for Priority Review by FDA
|
|
sillazze
|
163 |
82K |
22 |
02/02/23 |
02/02/23 |
ASX - By Stock
|
163
|
82K
|
22
|
|
ASX - By Stock
|
NEU |
Re:
Ann: Rett Syndrome NDA accepted for Priority Review by FDA
|
|
sillazze
|
163 |
82K |
8 |
02/02/23 |
02/02/23 |
ASX - By Stock
|
163
|
82K
|
8
|
|
ASX - By Stock
|
NEU |
Re:
Ann: Prader-Willi syndrome IND for NNZ-2591 approved by FDA
|
|
sillazze
|
16 |
10K |
36 |
25/01/23 |
25/01/23 |
ASX - By Stock
|
16
|
10K
|
36
|
|
ASX - By Stock
|
NEU |
Re:
Share Price
|
|
sillazze
|
11K |
5.4M |
11 |
12/01/23 |
12/01/23 |
ASX - By Stock
|
11K
|
5.4M
|
11
|
|
ASX - By Stock
|
NEU |
Re:
Share Price
|
|
sillazze
|
11K |
5.4M |
14 |
06/01/23 |
06/01/23 |
ASX - By Stock
|
11K
|
5.4M
|
14
|
|
ASX - By Stock
|
NEU |
Re:
Share Price
|
|
sillazze
|
11K |
5.4M |
22 |
06/01/23 |
06/01/23 |
ASX - By Stock
|
11K
|
5.4M
|
22
|
|
ASX - By Stock
|
NEU |
Re:
TROFINETIDE TRIALS UPDATE
|
|
sillazze
|
218 |
132K |
23 |
08/12/22 |
08/12/22 |
ASX - By Stock
|
218
|
132K
|
23
|
|
ASX - By Stock
|
NEU |
trial PW
|
|
sillazze
|
10 |
5.6K |
47 |
30/10/22 |
30/10/22 |
ASX - By Stock
|
10
|
5.6K
|
47
|
|
ASX - By Stock
|
NEU |
Re:
Share Price
|
|
sillazze
|
11K |
5.4M |
9 |
10/10/22 |
10/10/22 |
ASX - By Stock
|
11K
|
5.4M
|
9
|
|
ASX - By Stock
|
NEU |
Re:
Share Price
|
|
sillazze
|
11K |
5.4M |
6 |
10/10/22 |
10/10/22 |
ASX - By Stock
|
11K
|
5.4M
|
6
|
|
ASX - By Stock
|
NEU |
Re:
Share Price
|
|
sillazze
|
11K |
5.4M |
8 |
08/10/22 |
08/10/22 |
ASX - By Stock
|
11K
|
5.4M
|
8
|
|
ASX - By Stock
|
NEU |
Re:
Share Price
|
|
sillazze
|
11K |
5.4M |
5 |
10/09/22 |
10/09/22 |
ASX - By Stock
|
11K
|
5.4M
|
5
|
|
ASX - By Stock
|
NEU |
Re:
Share Price
|
|
sillazze
|
11K |
5.4M |
10 |
09/09/22 |
09/09/22 |
ASX - By Stock
|
11K
|
5.4M
|
10
|
|
ASX - By Stock
|
NEU |
Re:
Share Price
|
|
sillazze
|
11K |
5.4M |
50 |
21/07/22 |
21/07/22 |
ASX - By Stock
|
11K
|
5.4M
|
50
|
|
ASX - By Stock
|
NEU |
Re:
Possible reasons FDA won't approve Trofinetide
|
|
sillazze
|
13 |
7.4K |
9 |
17/07/22 |
17/07/22 |
ASX - By Stock
|
13
|
7.4K
|
9
|
|
ASX - By Stock
|
NEU |
Re:
Ann: Neuren commences Phase 2 trial of NNZ-2591 in Angelman
|
|
sillazze
|
30 |
16K |
7 |
12/07/22 |
12/07/22 |
ASX - By Stock
|
30
|
16K
|
7
|
|
ASX - By Stock
|
NEU |
Re:
Share Price
|
|
sillazze
|
11K |
5.4M |
24 |
10/07/22 |
10/07/22 |
ASX - By Stock
|
11K
|
5.4M
|
24
|
|
ASX - By Stock
|
NEU |
Re:
key point / upcoming breakthrough
|
|
sillazze
|
15 |
9.0K |
10 |
04/07/22 |
04/07/22 |
ASX - By Stock
|
15
|
9.0K
|
10
|
|
ASX - By Stock
|
NEU |
Re:
key point / upcoming breakthrough
|
|
sillazze
|
15 |
9.0K |
18 |
03/07/22 |
03/07/22 |
ASX - By Stock
|
15
|
9.0K
|
18
|
|
ASX - By Stock
|
NEU |
Re:
key point / upcoming breakthrough
|
|
sillazze
|
15 |
9.0K |
35 |
03/07/22 |
03/07/22 |
ASX - By Stock
|
15
|
9.0K
|
35
|
|
ASX - By Stock
|
NEU |
key point / upcoming breakthrough
|
|
sillazze
|
15 |
9.0K |
45 |
03/07/22 |
03/07/22 |
ASX - By Stock
|
15
|
9.0K
|
45
|
|
ASX - By Stock
|
NEU |
Re:
RNA-based+2591PW
|
|
sillazze
|
7 |
4.4K |
8 |
19/03/22 |
19/03/22 |
ASX - By Stock
|
7
|
4.4K
|
8
|
|
ASX - By Stock
|
NEU |
Re:
RNA-based+2591PW
|
|
sillazze
|
7 |
4.4K |
5 |
18/03/22 |
18/03/22 |
ASX - By Stock
|
7
|
4.4K
|
5
|
|
ASX - By Stock
|
NEU |
RNA-based+2591PW
|
|
sillazze
|
7 |
4.4K |
11 |
18/03/22 |
18/03/22 |
ASX - By Stock
|
7
|
4.4K
|
11
|
|
ASX - By Stock
|
NEU |
Neuren Pharmaceuticals Limited (NEU.XA)
|
|
sillazze
|
0 |
593 |
14 |
16/03/22 |
16/03/22 |
ASX - By Stock
|
0
|
593
|
14
|
|
ASX - By Stock
|
NEU |
Re:
Ann: 2021 Results - a transformational year for Neuren
|
|
sillazze
|
75 |
35K |
0 |
03/03/22 |
03/03/22 |
ASX - By Stock
|
75
|
35K
|
0
|
|
ASX - By Stock
|
NEU |
Re:
Ann: 2021 Results - a transformational year for Neuren
|
|
sillazze
|
75 |
35K |
4 |
02/03/22 |
02/03/22 |
ASX - By Stock
|
75
|
35K
|
4
|
|
ASX - By Stock
|
NEU |
Re:
Ann: 2021 Results - a transformational year for Neuren
|
|
sillazze
|
75 |
35K |
12 |
25/02/22 |
25/02/22 |
ASX - By Stock
|
75
|
35K
|
12
|
|
ASX - By Stock
|
NEU |
Re:
Ann: 2021 Results - a transformational year for Neuren
|
|
sillazze
|
75 |
35K |
1 |
25/02/22 |
25/02/22 |
ASX - By Stock
|
75
|
35K
|
1
|
|
ASX - By Stock
|
NEU |
Re:
Ann: 2021 Results - a transformational year for Neuren
|
|
sillazze
|
75 |
35K |
0 |
25/02/22 |
25/02/22 |
ASX - By Stock
|
75
|
35K
|
0
|
|
ASX - By Stock
|
NEU |
Re:
Ann: 2021 Results - a transformational year for Neuren
|
|
sillazze
|
75 |
35K |
34 |
25/02/22 |
25/02/22 |
ASX - By Stock
|
75
|
35K
|
34
|
|
ASX - By Stock
|
NEU |
Re:
Share Price
|
|
sillazze
|
11K |
5.4M |
7 |
25/11/21 |
25/11/21 |
ASX - By Stock
|
11K
|
5.4M
|
7
|
|
ASX - By Stock
|
NEU |
Re:
Share Price
|
|
sillazze
|
11K |
5.4M |
12 |
24/11/21 |
24/11/21 |
ASX - By Stock
|
11K
|
5.4M
|
12
|
|
ASX - By Stock
|
NEU |
Re:
Ann: Feedback on Angelman IND and submission of Pitt Hopkins IND
|
|
sillazze
|
7 |
5.5K |
10 |
07/10/21 |
07/10/21 |
ASX - By Stock
|
7
|
5.5K
|
10
|
|
ASX - By Stock
|
NEU |
Re:
Ann: Trading Halt
|
|
sillazze
|
117 |
47K |
1 |
10/09/21 |
10/09/21 |
ASX - By Stock
|
117
|
47K
|
1
|
|
ASX - By Stock
|
NEU |
Re:
Ann: Trading Halt
|
|
sillazze
|
117 |
47K |
19 |
10/09/21 |
10/09/21 |
ASX - By Stock
|
117
|
47K
|
19
|
|